Hubbry Logo
Autocrine signalingAutocrine signalingMain
Open search
Autocrine signaling
Community hub
Autocrine signaling
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Autocrine signaling
Autocrine signaling
Autocrine signaling
View on Wikipedia
from Wikipedia
A model of autocrine signaling.

Autocrine signaling is a form of cell signaling in which a cell secretes a hormone or chemical messenger (called the autocrine agent) that binds to autocrine receptors on that same cell, leading to changes in the cell.[1] This can be contrasted with paracrine signaling, intracrine signaling, or classical endocrine signaling.

Examples

[edit]

An example of an autocrine agent is the cytokine interleukin-1 in monocytes. When interleukin-1 is produced in response to external stimuli, it can bind to cell-surface receptors on the same cell that produced it.[citation needed]

Another example occurs in activated T cell lymphocytes, i.e., when a T cell is induced to mature by binding to a peptide:MHC complex on a professional antigen-presenting cell and by the B7:CD28 costimulatory signal. Upon activation, "low-affinity" IL-2 receptors are replaced by "high-affinity" IL-2 receptors consisting of α, β, and γ chains. The cell then releases IL-2, which binds to its own new IL-2 receptors, causing self-stimulation and ultimately a monoclonal population of T cells. These T cells can then go on to perform effector functions such as macrophage activation, B cell activation, and cell-mediated cytotoxicity.[citation needed]

Cancer

[edit]

Tumor development is a complex process that requires cell division, growth, and survival. One approach used by tumors to upregulate growth and survival is through autocrine production of growth and survival factors. Autocrine signaling plays critical roles in cancer activation and also in providing self-sustaining growth signals to tumors.[citation needed]

In the Wnt pathway

[edit]

Normally, the Wnt signaling pathway leads to stabilization of β-catenin through inactivation of a protein complex containing the tumor suppressors APC and Axin. This destruction complex normally triggers β-catenin phosphorylation, inducing its degradation. De-regulation of the autocrine Wnt signaling pathway via mutations in APC and Axin have been linked to activation of various types of human cancer.[2][3] Genetic alterations that lead to de-regulation of the autocrine Wnt pathway result in transactivation of epidermal growth factor receptor (EGFR) and other pathways, in turn contributing to proliferation of tumor cells. In colorectal cancer, for example, mutations in APC, axin, or β-catenin promote β-catenin stabilization and transcription of genes encoding cancer-associated proteins. Furthermore, in human breast cancer, interference with the de-regulated Wnt signaling pathway reduces proliferation and survival of cancer. These findings suggest that interference with Wnt signaling at the ligand-receptor level may improve the effectiveness of cancer therapies.[3]

IL-6

[edit]

Interleukin 6 (acronym: IL-6) is a cytokine that is important for many aspects of cellular biology including immune responses, cell survival, apoptosis, as well as proliferation.[4] Several studies have outlined the importance of autocrine IL-6 signaling in lung and breast cancers. For example, one group found a positive correlation between persistently activated tyrosine-phosphorylated STAT3 (pSTAT3), found in 50% of lung adenocarcinomas, and IL-6. Further investigation revealed that mutant EGFR could activate the oncogenic STAT3 pathway via upregulated IL-6 autocrine signaling.[5]

Similarly, HER2 overexpression occurs in approximately a quarter of breast cancers and correlates with poor prognosis. Recent research revealed that IL-6 secretion induced by HER2 overexpression activated STAT3 and altered gene expression, resulting in an autocrine loop of IL-6/STAT3 expression. Both mouse and human in vivo models of HER2-overexpressing breast cancers relied critically on this HER2–IL-6–STAT3 signaling pathway.[6] Another group found that high serum levels of IL-6 correlated with poor outcome in breast cancer tumors. Their research showed that autocrine IL-6 signaling induced malignant features in Notch-3 expressing mammospheres.[7]

IL-7

[edit]

A study demonstrates how the autocrine production of the IL-7 cytokine mediated by T-cell acute lymphoblastic leukemia (T-ALL) can be involved in the oncogenic development of T-ALL and offer novel insights into T-ALL spreading. [8]

VEGF

[edit]

Another agent involved in autocrine cancer signaling is vascular endothelial growth factor (VEGF). VEGF, produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma cells.[9] Evidence shows that autocrine VEGF is involved in two major aspects of invasive carcinoma: survival and migration. Moreover, it was shown that tumor progression selects for cells that are VEGF-dependent, challenging the belief that VEGF's role in cancer is limited to angiogenesis. Instead, this research suggests that VEGF receptor-targeted therapeutics may impair cancer survival and invasion as well as angiogenesis.[9][10]

Promotion of metastasis

[edit]

Metastasis is a major cause of cancer deaths, and strategies to prevent or halt invasion are lacking. One study showed that autocrine PDGFR signaling plays an essential role in epithelial-mesenchymal transition (EMT) maintenance in vitro, which is known to correlate well with metastasis in vivo. The authors showed that the metastatic potential of oncogenic mammary epithelial cells required an autocrine PDGF/PDGFR signaling loop, and that cooperation of autocrine PDGFR signaling with oncogenic was required for survival during EMT. Autocrine PDGFR signaling also contributes to maintenance of EMT, possibly through activation of STAT1 and other distinct pathways. In addition, expression of PDGFRα and -β correlated with invasive behavior in human mammary carcinomas.[11] This indicates the numerous pathways through which autocrine signaling can regulate metastatic processes in a tumor.

Development of therapeutic targets

[edit]

The growing knowledge behind the mechanism of autocrine signaling in cancer progression has revealed new approaches for therapeutic treatment. For example, autocrine Wnt signaling could provide a novel target for therapeutic intervention by means of Wnt antagonists or other molecules that interfere with ligand-receptor interactions of the Wnt pathway.[2][3] In addition, VEGF-A production and VEGFR-2 activation on the surface of breast cancer cells indicates the presence of a distinct autocrine signaling loop that enables breast cancer cells to promote their own growth and survival by phosphorylation and activation of VEGFR-2. This autocrine loop is another example of an attractive therapeutic target.[9]

In HER2 overexpressing breast cancers, the HER2–IL-6–STAT3 signaling relationship could be targeted to develop new therapeutic strategies.[6] HER2 kinase inhibitors, such as lapatinib, have also demonstrated clinical efficacy in HER2 overexpressing breast cancers by disrupting a neuregulin-1 (NRG1)-mediated autocrine loop.[12]

In the case of PDGFR signalling, overexpression of a dominant-negative PDGFR or application of the cancer drug STI571 are both approaches being explored to therapeutically interference with metastasis in mice.[11]

In addition, drugs may be developed that activate autocrine signaling in cancer cells that would not otherwise occur. For example, a small-molecule mimetic of Smac/Diablo that counteracts the inhibition of apoptosis has been shown to enhance apoptosis caused by chemotherapeutic drugs through autocrine-secreted tumor necrosis factor alpha (TNFα). In response to autocrine TNFα signaling, the Smac mimetic promotes formation of a RIPK1-dependent caspase-8-activating complex, leading to apoptosis.[13]

Role in drug resistance

[edit]

Recent studies have reported the ability of drug-resistant cancer cells to acquire mitogenic signals from previously neglected autocrine loops, causing tumor recurrence.

For example, despite widespread expression of epidermal growth factor receptors (EGFRs) and EGF family ligands in non-small-cell lung cancer (NSCLC), EGFR-specific tyrosine kinase inhibitors such as gefitinib have shown limited therapeutic success. This resistance is proposed to be because autocrine growth signaling pathways distinct from EGFR are active in NSCLC cells. Gene expression profiling revealed the prevalence of specific fibroblast growth factors (FGFs) and FGF receptors in NSCLC cell lines, and found that FGF2, FGF9 and their receptors encompass a growth factor autocrine loop that is active in a subset of gefitinib-resistant NSCLC cell lines.[14]

In breast cancer, the acquisition of tamoxifen resistance is another major therapeutic problem. It has been shown that phosphorylation of STAT3 and RANTES expression are increased in response to tamoxifen in human breast cancer cells. In a recent study, one group showed that STAT3 and RANTES contribute to the maintenance of drug resistance by upregulating anti-apoptotic signals and inhibiting caspase cleavage. These mechanisms of STAT3-RANTES autocrine signaling suggest a novel strategy for management of patients with tamoxifen-resistant tumors.[15]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Autocrine signaling

View on Grokipedia
from Grokipedia
Autocrine signaling is a form of intercellular communication in which a cell produces and releases signaling molecules, or ligands, that bind to specific receptors on its own plasma membrane, thereby eliciting a response within the same cell to regulate its own functions such as growth, differentiation, or . This self-stimulatory process contrasts with , where ligands affect nearby cells, and endocrine signaling, which involves hormones traveling through the bloodstream to distant targets. The mechanism of autocrine signaling typically begins with the synthesis and secretion of ligands, such as growth factors or cytokines, into the , where they diffuse only a short distance before being captured by receptors on the producing cell due to spatial constraints like limited and high-affinity receptor binding. Upon binding, these ligand-receptor complexes activate intracellular signaling pathways, often involving cascades of , second messengers like cAMP or calcium ions, and ultimately alterations in or enzymatic activity that modulate cellular behavior. For instance, in many systems, autocrine loops can form positive feedback mechanisms that amplify signals, as seen with (EGF) binding to EGFR on the same cell to promote proliferation. Autocrine signaling plays critical roles across physiological and pathological contexts, enabling rapid self-regulation in response to local environmental cues. In development and tissue homeostasis, it supports neuronal morphogenesis, such as (BDNF) promoting growth in hippocampal neurons, and (VEGF) maintaining endothelial cell integrity. In the , autocrine cytokine signaling, like interleukin-2 (IL-2) on T cells, amplifies activation and clonal expansion during responses to pathogens. However, dysregulation of autocrine pathways contributes to diseases; in cancer, tumor cells often exploit autocrine loops involving transforming growth factor-β (TGF-β) or Wnt signaling to drive uncontrolled proliferation, invasion, and resistance to . In cardiac remodeling, autocrine factors like fibroblast growth factors (FGFs) influence and in cardiomyocytes and fibroblasts, highlighting therapeutic potential for targeting these loops in .

Fundamentals

Definition and Characteristics

Autocrine signaling is a mode of cellular communication in which a cell produces and secretes signaling molecules, known as autocrine ligands, that bind to and activate receptors on the surface of the same cell, thereby eliciting an intracellular response without requiring input from neighboring or distant cells. This self-regulatory process enables cells to modulate their own behavior, such as proliferation, differentiation, or survival, through direct feedback mechanisms. Key characteristics of autocrine signaling include its capacity for self-stimulation, which amplifies or sustains cellular responses independently of external cues, and its prevalence in scenarios where cells operate in isolation or low-density conditions. For instance, growth factors like (PDGF) and transforming growth factor-beta (TGF-β) serve as common autocrine ligands; PDGF binds to PDGF receptors on the producing cell to promote self-sufficient growth, while TGF-β interacts with its receptors to regulate cellular processes such as production. Unlike , which targets nearby cells, or endocrine signaling, which affects distant targets via the bloodstream, autocrine signaling is inherently local and self-directed. From an evolutionary perspective, autocrine signaling offers advantages through rapid feedback loops that enhance cell autonomy, particularly in dynamic or isolated environments where paracrine or endocrine signals may be unreliable, allowing cells to initiate timely responses and avoid growth inhibition at low densities via mechanisms akin to Allee effects. The basic process of autocrine signaling begins with the secretion of a from the cell into the , followed by and binding to specific receptors on the same cell's , which triggers intracellular cascades to produce the desired response. This loop can be visualized as a closed circuit: ligand release → receptor activation → downstream signaling → potential reinforcement of ligand production.

Distinction from Other Signaling Types

Autocrine signaling differs from other modes of cellular communication in that the signaling molecule acts on the same cell that secretes it, enabling self-regulation without reliance on external cues. This contrasts with , where molecules diffuse over short distances to affect nearby cells; endocrine signaling, where hormones travel via the bloodstream to distant targets; and juxtacrine signaling, which requires direct physical contact between adjacent cells. The following table summarizes key distinctions among these signaling types:
Signaling TypeTarget CellsMode of TransmissionFunctional Role Example
AutocrineSame cellLocal diffusion to surface receptorsAutonomous feedback loops for control
ParacrineNearby cellsShort-range diffusionCoordination of local tissue responses, such as
EndocrineDistant cellsCirculation through bloodstreamMaintenance of systemic physiological balance, like regulation
JuxtacrineAdjacent cellsDirect membrane-membrane contactPrecise cell-cell interactions, including immune recognition
Functionally, autocrine signaling promotes independent cellular decision-making, such as amplifying internal responses to environmental changes, whereas paracrine mechanisms foster localized intercellular harmony within tissues, and endocrine pathways ensure organism-wide integration. Juxtacrine signaling supports contact-dependent processes that demand spatial proximity for accuracy. These differences highlight autocrine's unique role in self-referential control, distinct from the relational dynamics of other types. In certain contexts, boundaries between signaling modes can blur; for example, in dense cell populations, autocrine ligands may spill over to nearby cells via , mimicking paracrine effects, influenced by factors like rate and intercellular . Molecules such as cytokines can also switch modes based on concentration and microenvironment, exhibiting hybrid behaviors. The of autocrine signaling was introduced by Michael B. Sporn and George J. Todaro in their 1980 paper, where they described it as a mechanism of self-stimulation in transformed cells, laying the foundation for understanding autonomous cellular regulation.

Molecular Mechanisms

Key Components Involved

Autocrine signaling relies on specific molecular components that enable a cell to communicate with itself through the secretion and reception of signaling molecules. The primary elements include ligands, receptors, intracellular mediators, and regulatory mechanisms, each contributing to the precise control of cellular responses. Ligands in autocrine signaling are typically soluble molecules secreted by the cell and capable of binding to receptors on the same cell surface. Common types include cytokines, such as (e.g., IL-1), which mediate inflammatory and proliferative responses in epithelial cells, and growth factors, such as (EGF), which promotes and survival. These ligands are synthesized as precursors in the and processed through the Golgi apparatus before release via , ensuring their availability in the for immediate recapture. For instance, EGF and related ligands like transforming growth factor-alpha (TGF-α) and heparin-binding EGF (HB-EGF) form autocrine loops that sustain signaling in various cell types, including and fibroblasts. Receptors for autocrine ligands are predominantly transmembrane proteins located on the cell surface, designed to detect and transduce signals from extracellular ligands into intracellular responses. A key class is receptor kinases (RTKs), exemplified by the (EGFR), a 170-kDa with an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular kinase domain. Upon ligand binding, EGFR undergoes dimerization and autophosphorylation, initiating downstream cascades. Post-binding, these receptors are internalized through clathrin-mediated endocytosis, where ligand-receptor complexes are endocytosed into vesicles that may recycle the receptor or direct it to lysosomes for degradation, thereby modulating signal duration. This internalization mechanism is crucial for EGFR in autocrine contexts, as it allows sustained but regulated signaling from endosomal compartments. Intracellular mediators translate receptor activation into amplified cellular effects, often through second messengers that propagate and intensify the signal. In autocrine pathways involving G protein-coupled receptors, (cAMP) serves as a second messenger, generated by adenylate cyclase and activating to influence and . Similarly, inositol trisphosphate (IP3), produced by hydrolysis of , mobilizes calcium from intracellular stores, enhancing signal amplification through calcium-dependent enzymes like . These mediators ensure that autocrine signals, such as those from growth factors, elicit robust responses like proliferation or differentiation without requiring external inputs. Regulatory elements maintain homeostasis by preventing excessive autocrine stimulation, primarily through feedback inhibition and receptor modulation. Negative feedback loops often involve ligand-receptor interactions that suppress further ligand production or receptor activity; for example, binding of a ligand like C-type natriuretic peptide to its receptor inhibits downstream hypertrophic signals in cardiac cells. Receptor downregulation, achieved via ligand-induced endocytosis and lysosomal degradation, reduces surface receptor density, as seen with EGFR where ubiquitination targets internalized complexes for destruction, thereby attenuating prolonged signaling. These mechanisms collectively ensure that autocrine signaling remains balanced, avoiding pathological overactivation.

Common Signaling Pathways

Autocrine signaling frequently engages several canonical intracellular pathways to transduce self-secreted ligand signals into cellular responses, with the JAK-STAT, MAPK/ERK, and PI3K-Akt pathways being among the most prominent. These pathways are activated downstream of receptors such as cytokine receptors and receptor tyrosine kinases (RTKs), which bind autocrine ligands like or growth factors. The mechanisms involve sequential events that amplify and propagate the signal from the to the nucleus, enabling rapid changes. The JAK-STAT pathway is a key mediator in autocrine signaling, particularly for cytokines. Upon ligand binding to a dimeric cytokine receptor, the associated Janus kinases (JAKs) undergo transphosphorylation and activation, recruiting and phosphorylating signal transducer and activator of transcription (STAT) proteins at tyrosine residues. Phosphorylated STATs then dimerize, translocate to the nucleus, and bind to specific DNA sequences to regulate target gene transcription, such as those involved in proliferation and survival. This linear cascade allows for direct signal transmission without extensive intermediaries, ensuring swift responses to autocrine cues. In the MAPK/ERK pathway, autocrine activation typically begins with ligand-induced dimerization and autophosphorylation of RTKs, leading to recruitment of adapter proteins like Grb2 and Sos. This facilitates guanine nucleotide exchange on Ras, promoting its GTP-bound active state, which then recruits and activates Raf kinase. Raf phosphorylates and activates MEK1/2, which in turn phosphorylates ERK1/2 at dual threonine and tyrosine residues, enabling ERK nuclear translocation and phosphorylation of transcription factors that drive cell proliferation signals. The multi-tiered kinase cascade amplifies the initial signal, with each step exhibiting ultrasensitivity due to distributive phosphorylation mechanisms. The PI3K-Akt pathway is commonly activated in autocrine loops via RTKs or G-protein-coupled receptors binding growth factors. Ligand engagement recruits and activates (PI3K), which phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the plasma membrane. PIP3 then recruits and activates Akt (also known as PKB) by facilitating its phosphorylation at Thr308 and Ser473 by PDK1 and mTORC2, respectively. Activated Akt phosphorylates downstream targets like FOXO transcription factors and GSK3β, promoting cell survival, growth, and inhibition of . This pathway's second messengers provide spatial specificity to the signal. These pathways often exhibit crosstalk, integrating signals for nuanced cellular outcomes in autocrine contexts. For instance, activated STATs can transcriptionally upregulate PI3K components, enhancing Akt signaling, while ERK can phosphorylate and inhibit STAT activity, fine-tuning responses. Similarly, Ras activation in the MAPK pathway can PI3K , linking proliferation and signals. Such integrations occur at multiple levels, including shared adapters and feedback loops, allowing autocrine signals to elicit context-dependent effects. Kinetic modeling of these kinase cascades highlights their dynamic regulation, particularly in phosphorylation steps central to signal propagation. A simple Michaelis-Menten approximation for the rate of substrate phosphorylation in a cascade is given by: d[P]dt=k⋅[kinase]⋅[substrate]\frac{d[P]}{dt} = k \cdot [\text{kinase}] \cdot [\text{substrate}] where [P][P] is the phosphorylated product concentration, kk is the rate constant, [kinase][\text{kinase}] is the active kinase level, and [substrate][\text{substrate}] is the unphosphorylated form; this bilinear form underscores the amplification potential but assumes steady-state conditions without saturation. More detailed models incorporate ultrasensitivity from dual phosphorylation, as seen in ERK activation.

Physiological Roles

In Development and Tissue Homeostasis

Autocrine signaling plays a pivotal role in embryonic development by supporting self-renewal and facilitating tissue patterning during . In embryonic stem cells (ESCs), autocrine secretion of factors such as (LIF) and Wnt ligands maintains pluripotency and prevents premature differentiation, ensuring the expansion of pools essential for and lineage commitment. For instance, in mouse ESCs, autocrine Wnt signaling inhibits the transition to epiblast stem cells, thereby stabilizing the naive pluripotent state critical for early embryonic patterning. Similarly, during , autocrine loops contribute to precise morphogenetic events; in the developing heart, an FGF autocrine circuit in second heart field regulates outflow tract alignment and cushion formation, coordinating myocardial and endocardial interactions for proper arterial pole development. In adult tissue , autocrine signaling sustains balanced cellular proliferation and function across various organs. In the , rely on autocrine signaling through the (EGFR) by ligands such as α (TGFα) to drive proliferation in basal layers, maintaining the stratified architecture and barrier integrity essential for skin . This process involves downstream activation of PI3K and pathways, which promote cell and renewal while preventing excessive . In the , beta cells exhibit autocrine insulin signaling that enhances their , proliferation, and secretory capacity, thereby supporting glucose ; insulin binds to its receptor on the same cell, activating IRS-2-mediated pathways that mitigate endoplasmic reticulum stress and promote adaptation to metabolic demands. Autocrine mechanisms also enforce regulatory balance by modulating to avert uncontrolled growth and ensure tissue integrity. For example, autocrine transforming growth factor-beta (TGF-β) in hepatocytes induces arrest and via Smad-dependent repression of proliferation genes and activation of pro-apoptotic , thereby limiting hepatic overgrowth and maintaining organ size during regeneration. This inhibitory feedback prevents , integrating with proliferative signals to achieve in renewing tissues like the liver. Experimental evidence from genetic models underscores these roles, revealing disrupted upon autocrine pathway interruption. In knockouts lacking Fgf8 in the second heart field, ablation of the autocrine FGF loop leads to and defective outflow tract septation, with reduced mesenchymal cell invasion and impaired endothelial-to-mesenchymal transition, highlighting its necessity for cardiac patterning. Likewise, conditional knockout of Bmpr1a in epithelium disrupts autocrine BMP signaling, causing diminished distal bud proliferation, increased , and alveolar simplification, which collectively impair branching and gas exchange structure formation. These findings demonstrate how autocrine loops fine-tune developmental timing and spatial organization to prevent congenital defects.

In Immune Regulation

Autocrine signaling plays a pivotal role in immune regulation by enabling immune cells to self-stimulate through secreted cytokines, thereby fine-tuning , proliferation, and suppression mechanisms essential for mounting effective responses while preventing overactivation. In this context, cytokines such as interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β) serve as key ligands that bind to receptors on the same cell, amplifying or modulating intracellular pathways like JAK-STAT and to control immune . In T-cell activation, autocrine IL-2 signaling is crucial for driving clonal expansion following recognition by the . Upon activation, T cells produce IL-2, which binds to the high-affinity on the same cell, triggering STAT5 phosphorylation and promoting progression through upregulation of cyclins and downregulation of cell cycle inhibitors. This autocrine loop ensures sustained proliferation during the primary , particularly in CD4+ and CD8+ T cells, enabling rapid amplification of antigen-specific clones without relying solely on paracrine support from other cells. Seminal studies have demonstrated that disrupting this autocrine IL-2 pathway impairs T-cell expansion and memory formation, underscoring its necessity for adaptive immunity. Macrophages utilize autocrine TNF-α signaling to amplify inflammatory responses during or tissue . Activated macrophages secrete TNF-α, which engages TNFR1 receptors on the same cell, activating and MAPK pathways that enhance production of pro-inflammatory mediators like IL-1β and , thereby sustaining and intensifying the local inflammatory milieu. This self-reinforcing loop promotes macrophage polarization toward a pro-inflammatory M1 , facilitating clearance and recruitment of additional immune cells. Research highlights that autocrine TNF-α not only boosts immediate effector functions but also coordinates downstream for immune , as seen in models of bacterial challenge. For , autocrine TGF-β signaling in regulatory T cells (Tregs) is essential for suppressing excessive immune responses and maintaining self-tolerance. Tregs produce TGF-β, which binds to TGF-β receptors on their surface, activating SMAD2/3 pathways that stabilize expression—the master for Treg identity—and enhance suppressive functions through inhibition of effector T-cell proliferation via IL-2 downregulation. This autocrine mechanism ensures Treg stability in inflammatory environments, preventing uncontrolled auto-reactivity. Studies in + Treg models show that blocking autocrine TGF-β reduces suppressive capacity, emphasizing its role in balancing immunity. Dysregulation of these autocrine loops, such as excessive IL-2 or TNF-α signaling, has been linked to heightened immune activation in autoimmune conditions, though specific pathological details vary by disease.

Pathological Implications

In Cancer Progression

Autocrine signaling plays a pivotal role in cancer progression by enabling tumor cells to self-stimulate growth, survival, and invasive behaviors independent of external cues from the stroma or microenvironment. In tumorigenesis, autocrine loops involving growth factors like (PDGF) sustain uncontrolled proliferation in various malignancies, particularly gliomas, where PDGF overexpression activates PDGFRα on tumor cells, driving glial precursor expansion and without reliance on stromal support. This self-sustaining mechanism allows early tumor cells to evade growth limitations, fostering the establishment of aggressive neoplasms. Beyond initiation, autocrine signaling enhances tumor survival under harsh conditions such as hypoxia, a hallmark of solid tumors. Autocrine (VEGF) loops, for instance, activate VEGFR2 on tumor cells themselves, amplifying hypoxic inducible factor-1α (HIF-1α) signaling via pathways to promote cell viability and resistance to oxygen deprivation. This feed-forward mechanism not only supports intrinsic survival but also indirectly drives by sustaining VEGF production, enabling tumors to vascularize and expand. In , such loops have been shown to be essential for establishing fully angiogenic phenotypes. As of 2025, recent studies highlight autocrine TGF-β signaling contributing to resistance in solid tumors, with ongoing clinical trials targeting these loops to enhance treatment efficacy. Autocrine signaling further facilitates metastasis by inducing epithelial-mesenchymal transition (EMT), a process critical for tumor cell dissemination. Hepatocyte growth factor (HGF) acting in an autocrine manner on c-MET receptors triggers morphological changes, upregulates EMT markers like , and enhances invasion and migration in cancers such as and gastric cancer. This autocrine activation confers motility and anoikis resistance, allowing disseminated cells to colonize distant sites. Complementary examples include Wnt pathway autocrine activation in , where ligands like WNT7b stimulate β-catenin signaling to promote EMT and metastatic spread, correlating with poor prognosis. Similarly, in , autocrine IL-6 loops drive inflammatory signaling that supports proliferation and survival, exacerbating disease progression through sustained JAK/STAT pathway activation.

In Autoimmune and Inflammatory Diseases

In rheumatoid arthritis (RA), autocrine signaling involving interleukin-6 (IL-6) in synovial fibroblasts plays a central role in perpetuating chronic inflammation and joint destruction. Synovial fibroblasts, key effector cells in RA synovium, autonomously upregulate IL-6 production at the transcriptional level through spontaneous activation of NF-κB and RBP-Jκ transcription factors, independent of external cytokines such as tumor necrosis factor-alpha (TNF-α) or IL-1. This self-sustained IL-6 loop amplifies the inflammatory response by promoting fibroblast proliferation, matrix metalloproteinase secretion, and osteoclast activation, thereby contributing to cartilage degradation and bone erosion. In (MS), autocrine interferon-gamma (IFN-γ) signaling in T lymphocytes has been implicated in exacerbating demyelination by enhancing immune-mediated damage to the , though recent studies highlight its complex, dual pro- and anti-inflammatory effects. IFN-γ exerts autocrine and paracrine control over T-cell activity, inducing calcium influx that promotes T-cell proliferation and correlates with disease activity, particularly during relapses. This signaling increases class II expression on glial cells and stimulates macrophages to produce myelinotoxic molecules, thereby intensifying oligodendrocyte injury and plaque formation in the . Autocrine TNF-α loops in intestinal epithelial cells contribute to barrier dysfunction in (IBD). Under hypoxic conditions prevalent in inflamed mucosa, epithelial cells release TNF-α, which acts via basolateral TNF receptors to synergize with IFN-γ, reducing transepithelial resistance and increasing paracellular permeability. This autocrine activation upregulates expression and facilitates immune cell infiltration, promoting persistent mucosal inflammation characteristic of conditions like and . Recent post-2020 research highlights autocrine signaling in sustaining low-grade in , linking it to prolonged symptoms beyond acute infection. Persistent elevation of such as IL-6 and TNF-α, acting in autocrine and paracrine modes within tissues, drives chronic immune dysregulation, including Th1/Th17-biased responses and impaired repair, as evidenced by increased IL-7, IL-8, and IL-17F levels in affected individuals up to a year post-infection. These loops contribute to systemic effects like and , with blood profiles reflecting localized tissue persistence.

Therapeutic Applications

Targeting Autocrine Loops in Treatment

Autocrine signaling loops, where cells produce and respond to their own signaling molecules, represent attractive therapeutic targets in diseases driven by dysregulated self-stimulation, such as cancer and autoimmune disorders. Strategies to disrupt these loops primarily involve blocking key receptors or ligands using monoclonal antibodies or small molecule inhibitors, thereby halting downstream proliferative or survival signals. These approaches have shown clinical efficacy by sensitizing cells to apoptosis or immune attack, particularly in contexts where autocrine activation confers resistance to standard therapies. Monoclonal antibodies targeting receptor kinases are a cornerstone for interrupting autocrine loops in . , an anti-EGFR , binds to the extracellular domain of EGFR, preventing ligand binding such as EGF or and thereby blocking autocrine EGFR signaling that promotes proliferation in colorectal cancer cells. Approved for use in KRAS wild-type metastatic , has demonstrated improved when combined with , with response rates of approximately 57% in eligible patients, underscoring its role in dismantling autocrine-driven tumor growth. Small molecule inhibitors offer an alternative for targeting intracellular components of autocrine pathways, particularly in inflammatory conditions. In , where synovial fibroblasts engage in IL-6 autocrine signaling to sustain chronic inflammation via the JAK/STAT pathway, JAK inhibitors like and block JAK1/2/3 , thereby inhibiting IL-6-induced production and reducing joint damage. These agents, approved for moderate-to-severe , achieve clinical remission in approximately 30-40% of patients refractory to TNF inhibitors, highlighting their efficacy against autocrine-mediated persistence of disease. Other targeted examples include VEGF inhibitors for autocrine loops in solid tumors and IL-7 blockers in hematologic malignancies. , a against VEGF-A, neutralizes autocrine VEGF signaling that supports tumor cell survival and in and other cancers; in metastatic , it extends overall survival by 4-5 months when added to standard , though resistance can emerge via upregulated autocrine VEGF under hypoxia. In , where leukemic cells produce autocrine IL-7 to drive IL-7R signaling and resistance, IL-7R antagonists like lusvertikimab reduce leukemic burden in preclinical models by promoting and inhibiting proliferation. CAR-T cell therapies have been explored to overcome autocrine-mediated resistance in solid tumors, where immunosuppressive autocrine factors like TGF-β limit T-cell infiltration and persistence. Approaches incorporating IL-7 autocrine loops in CAR-T constructs aim to enhance resistance to tumor-derived suppression. These approaches build on successes in hematologic cancers to address autocrine barriers in broader applications.

Challenges and Future Directions

One major challenge in targeting autocrine signaling lies in the redundancy of signaling loops and extensive pathway , which enable cancer cells to activate compensatory mechanisms and develop resistance to inhibitors. For instance, (RTK) in tumors sustains aberrant , contributing to therapy resistance despite initial responses to targeted agents. Similarly, feedback activation between pathways, such as those involving EGFR and other RTKs, drives adaptive resistance by bypassing inhibited autocrine loops. Off-target effects further complicate treatment, as inhibitors designed for specific autocrine components often impact unrelated kinases or normal tissues, leading to without fully disrupting malignant signaling. Drug resistance mechanisms frequently involve upregulation of autocrine signaling post-treatment, allowing cells to evade inhibition. In , BRAF inhibitors like PLX-4720 induce resistance through increased secretion of galectin-1 (Gal-1), a for neuropilin-1 (NRP1), which forms an autocrine loop that sustains cell viability independently of BRAF activity. This upregulation promotes NRP1 and EGFR expression via , negatively regulating p27 to enhance proliferation, and can be reversed by combined NRP1 blockade. Such adaptive responses highlight the need for multi-target strategies to prevent autocrine-driven relapse. Future directions emphasize advanced delivery and modeling approaches to overcome these hurdles. enables ligand-specific delivery of siRNA to disrupt autocrine loops, as seen in systems targeting IGF-2 signaling to reduce tumor proliferation with minimal off-target impact. AI-driven modeling of autocrine , using tools like artificial neural , facilitates genome-scale simulations of intracellular signaling to predict resistance patterns and optimize interventions. editing via / offers precise disruption of autocrine pathways, such as by knocking out key receptors in signaling cascades to sensitize cells to therapy. Emerging research explores autocrine roles in neurodegeneration, particularly BDNF signaling in (AD). Recent studies (2023-2025) reveal that BDNF requires autocrine matrix metalloproteinase-9 (MMP-9) activity for maturation and TrkB activation in , a process impaired in AD where BDNF deficits exacerbate neuronal loss. Therapeutic activation of this autocrine circuit holds promise for restoring synaptic function and mitigating AD progression.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7955414/
  2. https://open.oregonstate.education/cellbiology/chapter/cell-signaling/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6066417/
  4. https://www.sciencedirect.com/science/article/pii/S0959438817303045
  5. https://doi.org/10.1523/JNEUROSCI.4682-14.2015
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4487014/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3388550/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC7835898/
  9. https://doi.org/10.1161/JAHA.120.019169
  10. https://www.ncbi.nlm.nih.gov/books/NBK26813/
  11. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/autocrine-signalling
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2732412/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8923455/
  14. https://www.ncbi.nlm.nih.gov/books/NBK538154/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4180974/
  16. https://pubmed.ncbi.nlm.nih.gov/7412807/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3094455/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC1301661/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC3996104/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC2914105/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC37350/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5447962/
  23. https://www.ncbi.nlm.nih.gov/books/NBK554403/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC8617206/
  25. https://www.nature.com/articles/s41392-021-00828-5
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC5634336/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC10754288/
  28. https://www.sciencedirect.com/science/article/pii/S1097276502005282
  29. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01827-6
  30. https://www.nature.com/articles/s41392-021-00791-1
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC5515553/
  32. https://pubmed.ncbi.nlm.nih.gov/16233950/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4030416/
  34. https://journals.biologists.com/dev/article/135/21/3599/18570/An-FGF-autocrine-loop-initiated-in-second-heart
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC11837477/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3712043/
  37. https://journals.physiology.org/doi/full/10.1152/ajpgi.2001.280.1.G139
  38. https://pubmed.ncbi.nlm.nih.gov/16414041/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6472684/
  40. https://pubmed.ncbi.nlm.nih.gov/35417685/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC3066460/
  42. https://pubmed.ncbi.nlm.nih.gov/35058362/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC2996554/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC7356964/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC2213134/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC10552796/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC3189547/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC8094702/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC3339540/
  50. https://pubmed.ncbi.nlm.nih.gov/16103078/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC4148093/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3613914/
  53. https://www.nature.com/articles/s41392-025-02415-4
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4832867/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC3565297/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC7893751/
  57. https://pubmed.ncbi.nlm.nih.gov/11154226/
  58. https://pubmed.ncbi.nlm.nih.gov/1991169/
  59. https://pubmed.ncbi.nlm.nih.gov/10329846/
  60. https://pubmed.ncbi.nlm.nih.gov/9345397/
  61. https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-024-03126-3
  62. https://www.gastrojournal.org/article/S0016-5085(98)70579-7/fulltext
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC10103649/
  64. https://www.mdpi.com/1422-0067/26/17/8432
  65. https://www.oncotarget.com/article/14012/text/
  66. https://aacrjournals.org/clincancerres/article/14/21/6963/73173/Autocrine-Production-of-Amphiregulin-Predicts
  67. https://www.nejm.org/doi/full/10.1056/NEJMoa0805019
  68. https://www.nature.com/articles/s41392-020-0116-z
  69. https://www.mdpi.com/2227-9059/13/10/2429
  70. https://www.tandfonline.com/doi/full/10.1080/25785826.2020.1770948
  71. https://www.nature.com/articles/s41598-025-94894-2
  72. https://pubmed.ncbi.nlm.nih.gov/25015210/
  73. https://www.oncotarget.com/article/1671/text/
  74. https://ashpublications.org/blood/article/143/26/2735/515436/The-IL-7R-antagonist-lusvertikimab-reduces
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC8141613/
  76. https://www.sciencedirect.com/science/article/pii/S2666379125004264
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC12196329/
  78. https://www.sciencedirect.com/science/article/abs/pii/S1368764622000838
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC8615814/
  80. https://www.mdpi.com/2072-6694/12/8/2218
  81. https://www.jci.org/articles/view/99257
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC12413497/
  83. https://www.nature.com/articles/s41467-022-30684-y
  84. https://www.sciencedirect.com/science/article/pii/S0925443923002387
  85. https://www.science.org/doi/10.1126/sciadv.adx2369
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC12084274/
  87. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2023.1247422/full
Add your contribution
Related Hubs
User Avatar
No comments yet.